Regeneron Pharmaceuticals Inc (REGN)

Debt-to-capital ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	1,982,900	1,982,600	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	—	—	0	—	—	—
Total stockholders’ equity	US$ in thousands	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000	11,089,700	10,504,400	9,755,900	9,444,700
Debt-to-capital ratio		0.07	0.07	0.08	0.08	0.08	0.08	0.09	0.09	0.10	0.10	0.12	0.14	0.15	0.16	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,982,900K ÷ ($1,982,900K + $25,973,100K)
= 0.07

The debt-to-capital ratio of Regeneron Pharmaceuticals, Inc. has shown a gradual decline over the past two years, decreasing from 0.12 in Q1 2022 to 0.09 in Q4 2023. This indicates that the company has been reducing its reliance on debt in relation to its total capital structure, which includes both debt and equity.

A lower debt-to-capital ratio signifies that Regeneron Pharmaceuticals is using less debt financing compared to its equity financing, which can be viewed positively by investors and creditors as it indicates a stronger financial position and lower financial risk. It suggests that the company may have a more conservative approach to managing its financial leverage and may have a stronger ability to meet its debt obligations.

Overall, the decreasing trend in the debt-to-capital ratio of Regeneron Pharmaceuticals, Inc. reflects a favorable financial position and prudent financial management, which may contribute to the company's long-term sustainability and stability in the pharmaceutical industry.